Isofluran Baxter
Isoflurane – Halogenated volatile anesthetic for general anesthesia
Isofluran Baxter is a volatile halogenated anesthetic agent used for the induction and maintenance of general anesthesia during surgical procedures. Delivered as an inhaled vapour through a specially calibrated vaporizer, isoflurane produces a state of deep unconsciousness, amnesia, and pain relief. This medication is administered exclusively in hospital operating rooms and intensive care settings by trained anesthesiology professionals. Understanding its uses, contraindications, and potential adverse effects is essential for patients preparing for surgery.
Quick Facts
Key Takeaways
- Isofluran Baxter is a halogenated volatile anesthetic delivered by inhalation through a calibrated vaporizer to induce and maintain general anesthesia during surgery.
- It must never be administered to patients with a known or suspected susceptibility to malignant hyperthermia, a rare but life-threatening condition that causes rapid, dangerous elevation in body temperature.
- Isoflurane is not recommended for induction of anesthesia in infants and children because it can irritate the airways and cause laryngospasm (throat muscle spasm).
- Patients should not drive or operate machinery for at least 24 hours after receiving isoflurane anesthesia, with potential cognitive effects lasting up to 6 days.
- Isoflurane can cause changes in liver function and, in rare cases, severe hepatic injury. Patients with pre-existing liver disease require careful monitoring.
What Is Isofluran Baxter and What Is It Used For?
Isoflurane is one of the most widely used inhaled anesthetic agents in modern medical practice. It belongs to the class of halogenated methyl ethyl ethers and has been a mainstay of anesthesia practice since its clinical introduction in the 1980s. The drug is included on the World Health Organization (WHO) Model List of Essential Medicines, reflecting its critical importance in global surgical care.
When a patient breathes in isoflurane vapour through a face mask or endotracheal tube connected to an anesthesia machine, the drug rapidly enters the bloodstream through the lungs. It then travels to the brain, where it acts on multiple receptor systems to produce its anesthetic effects. Specifically, isoflurane enhances the activity of inhibitory GABA-A receptors and glycine receptors while simultaneously blocking excitatory NMDA and nicotinic acetylcholine receptors. The result is a dose-dependent depression of the central nervous system that produces loss of consciousness, amnesia, immobility in response to surgical stimulation, and some degree of analgesia.
A key advantage of isoflurane is that the depth of anesthesia can be precisely and rapidly controlled by adjusting the concentration of vapour delivered through the vaporizer. When the anesthesiologist stops delivering the agent, patients typically begin to regain consciousness within minutes as the isoflurane is exhaled from the lungs. This controllability is one of the reasons isoflurane remains a popular choice among anesthesiologists worldwide.
How Isoflurane Works
Isoflurane acts primarily through modulation of ion channels in the central nervous system. Its principal mechanism involves potentiation of inhibitory neurotransmission and suppression of excitatory neurotransmission. The drug enhances the function of GABA-A receptors, which are the major inhibitory receptors in the brain, making neurons less excitable. Simultaneously, it inhibits glutamate receptors (particularly NMDA receptors), which mediate excitatory signaling.
Beyond the brain, isoflurane has important effects on other organ systems. It produces dose-dependent cardiovascular depression, causing a reduction in blood pressure primarily through peripheral vasodilation. It maintains cardiac output better than some other volatile agents, and cardiac rhythm remains relatively stable because isoflurane has a low potential for sensitizing the heart to catecholamines (adrenaline-type hormones). It also produces dose-dependent respiratory depression and provides some degree of skeletal muscle relaxation, which is beneficial during many types of surgery.
Isoflurane has a blood-gas partition coefficient of approximately 1.4, which means it has a moderately fast onset and recovery profile. The minimal alveolar concentration (MAC) – the standard measure of anesthetic potency – is approximately 1.15% in adults breathing oxygen, though this value decreases with age and with the concurrent use of other anesthetic agents such as opioids or nitrous oxide. Only about 0.2% of the administered dose undergoes hepatic metabolism via the cytochrome P450 enzyme CYP2E1, with the vast majority being exhaled unchanged. This minimal metabolism contributes to its favorable safety profile with respect to organ toxicity.
Approved Clinical Uses
Isofluran Baxter is indicated for the following clinical applications:
- Induction of general anesthesia – Although isoflurane can be used for inhalational induction in adults, this is less common in practice due to its pungent odor, which may cause coughing and airway irritation. Induction is typically achieved with an intravenous agent first.
- Maintenance of general anesthesia – This is the primary and most common use of isoflurane. Once the patient is asleep, isoflurane vapour is delivered continuously to maintain the desired depth of anesthesia throughout the surgical procedure.
- Sedation in intensive care units (ICU) – Some formulations of isoflurane (such as Sedaconda) are specifically designed for long-term sedation of mechanically ventilated patients in the ICU, using specialized administration devices.
Isoflurane is suitable for use in a wide range of surgical procedures, from minor outpatient operations to complex major surgeries. It is used in both adults and children, though specific precautions apply to pediatric patients, particularly regarding airway management during induction.
What Should You Know Before Taking Isofluran Baxter?
Contraindications
Isofluran Baxter must not be used in the following situations:
- Known allergy to isoflurane or other halogenated anesthetics – Patients with documented hypersensitivity to isoflurane or other volatile anesthetics such as sevoflurane, desflurane, enflurane, or halothane must not receive this medication. Allergic reactions can range from contact dermatitis and rash to severe anaphylactic reactions.
- Known or suspected susceptibility to malignant hyperthermia – This is an absolute contraindication. Malignant hyperthermia is a rare, inherited condition in which exposure to volatile anesthetics triggers uncontrolled skeletal muscle metabolism, leading to a rapid and potentially fatal rise in body temperature, severe metabolic acidosis, muscle rigidity, and organ failure. If you or any blood relative has ever experienced this condition, you must inform your healthcare team.
Malignant hyperthermia is a rare but life-threatening emergency that can occur during or shortly after anesthesia with volatile agents like isoflurane. Deaths have been reported in association with isoflurane-triggered malignant hyperthermia. If you or any family member has a history of this condition, inform your surgical team immediately. Treatment requires immediate discontinuation of the triggering agent and administration of intravenous dantrolene sodium.
Warnings and Precautions
Your anesthesiologist should be informed about the following conditions and risk factors, as they may require dose adjustments, additional monitoring, or selection of an alternative anesthetic agent:
- Mitochondrial disease – Patients with mitochondrial disorders (conditions affecting cellular energy production) may be at increased risk of complications during volatile anesthesia. Extra caution and monitoring are warranted.
- Liver disease – Patients with hepatitis, liver cirrhosis, or other hepatic conditions require careful assessment. Isoflurane can cause changes in liver function, and in rare cases, severe hepatic injury including hepatocellular necrosis has been reported. A history of unexplained liver dysfunction or jaundice following previous exposure to halogenated anesthetics is a particular concern.
- Recent general anesthesia – Patients who have recently undergone surgery under general anesthesia, particularly with halogenated agents, may have a heightened risk of hepatotoxicity with repeated exposure. The anesthesiologist will consider the timing and type of previous anesthetics.
- QT prolongation risk – Patients with a history of QT interval prolongation on electrocardiogram (ECG) or those taking medications that prolong the QT interval are at increased risk of developing cardiac arrhythmias during isoflurane anesthesia.
- Neuromuscular disorders – Patients with conditions such as Duchenne muscular dystrophy or myasthenia gravis require special consideration, as isoflurane can interact with the underlying muscle pathology and increase the risk of complications such as rhabdomyolysis (muscle breakdown) and hyperkalemia (dangerously elevated potassium).
- Recent miscarriage or termination of pregnancy – Isoflurane has a relaxant effect on uterine smooth muscle and may increase the risk of uterine bleeding in this context.
- Bronchial hyperreactivity – While isoflurane generally provides some bronchodilation, it can irritate the airways, particularly during induction, causing coughing, breath-holding, or bronchospasm in susceptible patients.
- Pediatric patients under 2 years – Young children, particularly infants, require extra vigilance due to the increased risk of laryngospasm and airway secretions with isoflurane. The drug is not recommended for inhalational induction of anesthesia in infants and young children.
Your anesthesiologist may administer a lower dose of isoflurane if you have low blood volume (hypovolemia), low blood pressure (hypotension), or are otherwise physically debilitated, as these conditions increase sensitivity to the cardiovascular effects of volatile anesthetics.
Isoflurane can irritate the mucous membranes of the mouth and airways, leading to increased saliva production and secretions from the trachea and upper airways. In children, this may lead to breathing difficulties and laryngospasm (spasm of the throat muscles). Your anesthesiologist may pre-treat your child with medication to reduce these effects.
Pregnancy, Breastfeeding, and Fertility
The use of isoflurane in pregnant and breastfeeding women requires careful consideration:
Pregnancy: There is limited clinical experience with isoflurane in pregnant women, and it should only be used when the potential benefits clearly outweigh the risks to the fetus. The exception is cesarean section, where lower doses of isoflurane may be administered as part of general anesthesia. Isoflurane relaxes uterine smooth muscle in a dose-dependent manner, which may increase the risk of uterine bleeding.
Breastfeeding: It is unknown whether isoflurane or its metabolites are excreted in human breast milk. As a precaution, breastfeeding should be avoided after surgery involving isoflurane anesthesia until advised otherwise by your healthcare provider.
Fertility: There is insufficient data to establish whether isoflurane affects human fertility. Animal studies have not demonstrated significant effects on reproductive capacity at clinically relevant exposures.
Driving and Operating Machinery
Patients must not drive or operate machinery for at least 24 hours after receiving isoflurane anesthesia. General anesthesia affects alertness, judgment, coordination, and reaction time. These cognitive effects may persist for up to 6 days after the procedure in some individuals. Patients should arrange for someone to accompany them home after surgery and should not make important decisions or sign legal documents during the immediate recovery period.
How Does Isofluran Baxter Interact with Other Drugs?
Informing your healthcare team about all medications you are taking – including prescription drugs, over-the-counter medicines, herbal supplements, and recreational substances – is critical for safe anesthesia. The following drug interactions are of particular clinical importance:
| Interacting Drug | Type of Interaction | Clinical Significance |
|---|---|---|
| Non-selective MAO inhibitors | Risk of hypertensive crisis | Must be discontinued at least 15 days before surgery. Concurrent use can cause severe, life-threatening hypertension and cardiovascular instability. |
| Beta-sympathomimetics (e.g., isoprenaline) | Risk of serious cardiac arrhythmias | While isoflurane has low potential to sensitize the heart to catecholamines compared to halothane, concurrent use of sympathomimetics can still cause dangerous irregular heartbeats. |
| Adrenaline (epinephrine) and noradrenaline | Increased risk of cardiac arrhythmias | Catecholamines should be used with caution during isoflurane anesthesia. Although the risk is lower than with halothane, high doses can provoke ventricular arrhythmias. |
| Beta-blockers | Enhanced hypotension and bradycardia | Both isoflurane and beta-blockers lower blood pressure and heart rate. The combination requires careful hemodynamic monitoring to avoid excessive cardiovascular depression. |
| Isoniazid (for tuberculosis) | Increased hepatotoxicity risk | Isoniazid induces CYP2E1, the enzyme that metabolizes isoflurane, potentially increasing the production of hepatotoxic metabolites. Close liver function monitoring is advised. |
| Amphetamines, ephedrine, appetite suppressants | Risk of hypertension | Indirect sympathomimetics can cause unpredictable blood pressure elevations during isoflurane anesthesia. Your doctor will advise when to stop these medications before surgery. |
| Neuromuscular blocking agents (muscle relaxants) | Potentiation of muscle relaxation | Isoflurane significantly enhances the effects of non-depolarizing muscle relaxants (e.g., rocuronium, atracurium). The anesthesiologist will reduce the dose of these agents accordingly. |
| Opioids (e.g., fentanyl, morphin, remifentanil) | Enhanced respiratory depression and anesthetic depth | Opioids reduce the MAC of isoflurane, meaning less isoflurane is needed. However, the combination increases the risk of respiratory depression, requiring careful ventilation monitoring. |
| Calcium channel blockers | Additive cardiovascular depression | Both agents lower blood pressure. Combined use may cause excessive hypotension. Hemodynamic monitoring and dose adjustment are required. |
| Benzodiazepines (e.g., diazepam, midazolam) | Enhanced sedation and respiratory depression | Benzodiazepines reduce the MAC of isoflurane and increase respiratory depression. Concurrent use requires careful dose titration and respiratory monitoring. |
Always inform your anesthesiologist and surgical team about every medication you take, including cold and cough remedies (many contain sympathomimetic agents like ephedrine), herbal supplements, and any recreational drugs. This information is essential for planning safe anesthesia.
What Is the Correct Dosage of Isofluran Baxter?
Unlike oral medications with fixed dose tablets, isoflurane is a continuously delivered inhaled agent whose concentration is adjusted in real-time by the anesthesiologist throughout the procedure. The depth of anesthesia is controlled by increasing or decreasing the inspired concentration (expressed as a percentage of the total gas mixture), with the response guided by clinical monitoring of the patient's vital signs, reflexes, and anesthetic depth indicators.
Adults
Induction of Anesthesia
In adults, isoflurane induction (when used) involves starting at concentrations of 0.5% and gradually increasing to 3.0% to produce surgical anesthesia. However, induction is more commonly achieved with an intravenous agent (such as propofol), after which isoflurane is introduced for maintenance. The pungent odor of isoflurane makes pure inhalational induction less comfortable for awake patients compared to sevoflurane.
Maintenance of Anesthesia
Surgical anesthesia is typically maintained with isoflurane concentrations of 1.0% to 2.5% when used with oxygen-nitrous oxide mixtures, or 1.5% to 3.5% when used with oxygen alone. The MAC (minimal alveolar concentration) for adults is approximately 1.15% in oxygen, decreasing with concurrent use of opioids, nitrous oxide, or other adjunct agents.
Children
Pediatric Dosing
Isoflurane is not recommended for induction of anesthesia in infants and young children due to the risk of airway irritation, coughing, breath-holding, and laryngospasm. Children should be induced with an intravenous agent or a more suitable volatile agent (e.g., sevoflurane) before transitioning to isoflurane for maintenance. Children generally require higher MAC values than adults – neonates have a MAC of approximately 1.6%, decreasing with age. The anesthesiologist may premedicate the child with atropine or glycopyrrolate to reduce airway secretions and prevent vagal-mediated bradycardia.
Elderly
Elderly Patients
The MAC of isoflurane decreases with advancing age. Elderly patients (over 65 years) typically require lower concentrations to achieve adequate anesthesia. For example, an 80-year-old patient may have a MAC approximately 30% lower than a young adult. Additionally, elderly patients are more susceptible to the cardiovascular depressant effects (hypotension, bradycardia) of isoflurane, necessitating careful titration and hemodynamic monitoring.
Overdose
If an excessive concentration of isoflurane is administered, the anesthesiologist will immediately stop the delivery and provide the patient with pure oxygen. Overdose manifests as profound hypotension, severe respiratory depression, and potentially cardiac arrest. The anesthesiology team will support the patient's blood pressure and cardiac function while the isoflurane is rapidly eliminated through the lungs. Because isoflurane is exhaled rather than metabolized, recovery from overdose is generally rapid once the agent is discontinued.
What Are the Side Effects of Isofluran Baxter?
The side effects of isoflurane range from common, expected physiological responses to rare but potentially life-threatening reactions. The following frequency-based classification summarizes the known adverse effects:
Most Common Side Effects
- Bronchospasm (constriction of airways causing breathing difficulty)
- Elevated blood glucose (hyperglycemia)
- Elevated blood potassium (hyperkalemia)
- Post-operative nausea and vomiting
- Shivering and chills
Cardiac and Cardiovascular Effects
- Low blood pressure (hypotension)
- Irregular heartbeat (arrhythmias including ventricular tachycardia)
- Abnormal ECG including QT prolongation
- Increased or decreased heart rate
- Bleeding (related to vasodilation)
- Cardiac arrest (very rare, primarily reported in children post-operatively)
Respiratory and Airway Effects
- Laryngospasm (spasm of throat muscles, especially in children)
- Slow and shallow breathing (respiratory depression)
- Shortness of breath (dyspnea)
- Wheezing
- Increased airway secretions
Hepatic (Liver) Effects
- Abnormal liver function tests
- Elevated bilirubin levels
- Hepatic injury including hepatocellular necrosis
Other Reported Effects (Frequency Not Known)
- Carboxyhemoglobin formation (from interaction with dry CO2 absorbents)
- Anaphylactic reaction (severe allergic reaction)
- Agitation, mood changes, confusion
- Seizures, impaired cognitive function
- Facial swelling, contact dermatitis, skin rash
- Elevated creatinine and creatine kinase levels
- Ileus (temporary paralysis of intestinal muscles)
- Rhabdomyolysis (muscle breakdown)
- Myoglobinuria (myoglobin in urine)
- Malignant hyperthermia (life-threatening temperature elevation)
- Chest discomfort
- Elevated inorganic fluoride levels
- Abnormal EEG findings
In rare cases, abnormal heart rhythms (arrhythmias) and deaths have been reported in children shortly after surgery involving inhaled anesthetic agents, including isoflurane. Parents should be informed of this rare risk and should promptly report any unusual symptoms in their child after surgery.
It is important to note that many of the cardiovascular and respiratory effects listed above are expected, dose-dependent pharmacological actions of isoflurane rather than true "side effects." The anesthesiologist continuously monitors these parameters during surgery and adjusts the anesthetic accordingly. Most effects resolve rapidly once the isoflurane is discontinued.
How Should You Store Isofluran Baxter?
Isofluran Baxter is a clear, colorless liquid that is stored in its original sealed container at the hospital pharmacy or within the anesthesia department. No special temperature requirements apply for storage. The medication must be used before the expiration date printed on the label (which refers to the last day of the indicated month).
As with all medications, Isofluran Baxter must be kept out of the sight and reach of children. The product should not be disposed of via drains or household waste. Hospital pharmacies follow established pharmaceutical waste disposal protocols to protect the environment, as volatile anesthetics are potent greenhouse gases. Modern operating rooms are increasingly equipped with waste anesthetic gas scavenging systems to capture exhaled isoflurane and minimize atmospheric release.
What Does Isofluran Baxter Contain?
Isoflurane (chemical name: 1-chloro-2,2,2-trifluoroethyl difluoromethyl ether) is a halogenated methyl ethyl ether with the molecular formula C3H2ClF5O. It is a clear, colorless liquid with a slightly pungent, ethereal odor. It is non-flammable at clinical concentrations but requires specific handling precautions in the operating room.
Package Sizes
Isofluran Baxter is available in the following package sizes:
- 1 × 100 mL bottle
- 1 × 250 mL bottle
- 6 × 250 mL bottles
Not all package sizes may be marketed in every country.
Administration Equipment
Isoflurane must only be administered using a vaporizer specifically calibrated for isoflurane. Using a vaporizer designed for a different anesthetic agent could result in a dangerous over- or underdose. The anesthesia machine must include equipment for maintaining a patent airway, assisted ventilation, oxygen delivery, and cardiopulmonary resuscitation. Only trained anesthesiology professionals who are knowledgeable in isoflurane's pharmacology should administer this agent.
Like other halogenated anesthetics, isoflurane can interact with dried-out soda lime (carbon dioxide absorbent) in the anesthesia breathing circuit to produce carbon monoxide, which poses a risk of elevated carboxyhemoglobin levels. In rare cases, extreme heat, smoke, or fire in the anesthesia machine have been reported with desiccated absorbents, particularly those containing potassium hydroxide. Fresh (moist) CO2 absorbent must always be used, and absorbent should be replaced at regular intervals regardless of the color indicator status.
Frequently Asked Questions About Isofluran Baxter
Isofluran Baxter is a volatile inhaled anesthetic used to induce and maintain general anesthesia during surgical procedures. It is delivered as a vapour through a specially calibrated vaporizer and breathing circuit. It produces unconsciousness, amnesia, and pain relief so that patients can undergo surgery safely. It is one of the most widely used anesthetic agents worldwide and is listed on the WHO Model List of Essential Medicines.
Malignant hyperthermia is a rare, life-threatening genetic condition in which exposure to volatile anesthetics like isoflurane triggers uncontrolled skeletal muscle metabolism. This leads to a rapid and dangerous rise in body temperature, muscle rigidity, metabolic acidosis, and potential organ failure. Patients with a personal or family history of malignant hyperthermia must not receive isoflurane or any other volatile anesthetic. The condition requires immediate treatment with intravenous dantrolene sodium.
Recovery from isoflurane anesthesia is generally rapid. Most patients begin to regain consciousness within a few minutes after the anesthesiologist stops delivering the vapour. However, full mental alertness may take several hours to return. Patients should not drive or operate machinery for at least 24 hours after anesthesia, and cognitive effects may persist for up to 6 days in some individuals. You should arrange for someone to take you home after your procedure.
There is limited clinical experience with isoflurane in pregnant women, and it should only be used during pregnancy if the benefits clearly outweigh the risks. Lower doses of isoflurane may be used during cesarean section deliveries. Isoflurane relaxes uterine smooth muscle, which may increase the risk of bleeding. It is unknown whether isoflurane passes into breast milk, so breastfeeding should be avoided after receiving isoflurane anesthesia until advised otherwise by a healthcare provider.
The most common side effects include airway constriction (bronchospasm), increased blood sugar levels, and elevated blood potassium levels. Post-operative nausea and vomiting, shivering, and transient liver enzyme elevations are also frequently observed. In children, isoflurane may cause laryngospasm (throat muscle spasm) and increased airway secretions. Most side effects are mild to moderate and resolve after the anesthetic is discontinued.
Isoflurane has several characteristics that distinguish it from other volatile anesthetics such as sevoflurane and desflurane. It has a pungent odor that makes it less suitable for inhalational induction, particularly in children. However, it provides excellent muscle relaxation, has minimal cardiac sensitization to catecholamines compared to halothane, and undergoes very little hepatic metabolism (only 0.2%), reducing the risk of hepatotoxicity. Its cost-effectiveness also makes it widely used in resource-limited settings globally.
Isofluran Baxter does not require any special storage conditions. It should be stored in its original container, kept out of the reach of children, and used before the expiration date printed on the label. The liquid should be kept tightly sealed when not in use. Unused or expired medication should be disposed of according to local pharmaceutical waste regulations and should not be poured down drains or disposed of with household waste.
References
- World Health Organization. WHO Model List of Essential Medicines – 23rd List, 2023. Geneva: WHO; 2023.
- European Medicines Agency (EMA). Isoflurane – Summary of Product Characteristics. European public assessment reports. Available at: ema.europa.eu.
- Eger EI 2nd. Isoflurane: A Review. Anesthesiology. 1981;55(5):559-576. doi:10.1097/00000542-198111000-00014
- Hopkins PM. Malignant hyperthermia: pharmacology of triggering. British Journal of Anaesthesia. 2011;107(1):48-56. doi:10.1093/bja/aer132
- Sakai EM, Connolly LA, Klauck JA. Inhalation anesthesiology and volatile liquid anesthetics: focus on isoflurane, desflurane, and sevoflurane. Pharmacotherapy. 2005;25(12):1773-1788. doi:10.1592/phco.2005.25.12.1773
- British National Formulary (BNF). Isoflurane. National Institute for Health and Care Excellence. Updated 2025.
- American Society of Anesthesiologists (ASA). Practice Guidelines for Preoperative Fasting and the Use of Pharmacologic Agents to Reduce the Risk of Pulmonary Aspiration. Anesthesiology. 2017;126(3):376-393.
- Rosenberg H, Pollock N, Schiemann A, Bulger T, Stowell K. Malignant hyperthermia: a review. Orphanet Journal of Rare Diseases. 2015;10:93. doi:10.1186/s13023-015-0310-1
- Njoku D, Laster MJ, Gong DH, Eger EI 2nd, Reed GF, Martin JL. Biotransformation of halothane, enflurane, isoflurane, and desflurane to trifluoroacetylated liver proteins. Anesthesia & Analgesia. 1997;84(1):173-178.
- U.S. Food and Drug Administration (FDA). Drug Safety Communication: FDA review results in new warnings about using general anesthetics and sedation drugs in young children and pregnant women. 2016.
Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising licensed specialist physicians with expertise in anesthesiology, clinical pharmacology, and perioperative medicine.
Content developed by physicians with specialization in anesthesiology and pharmacology, based on current EMA, FDA, and WHO guidelines.
Independently reviewed by the iMedic Medical Review Board for clinical accuracy, completeness, and adherence to international medical standards.
All claims verified against peer-reviewed literature using the GRADE evidence framework. Evidence Level 1A where applicable.
No pharmaceutical company sponsorship or commercial funding. All content is editorially independent.